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ABSTRACT
The association of adult height with mortality has been extensively investigated in the general population,
but little is known about this relationship among dialysis patients. We explored the relationship between
height and mortality in a retrospective cohort study of 1,171,842 adults who began dialysis in the United
States from 1995 to 2008 and were followed until December 31, 2010. We evaluated height-mortality
associations in sex-speciﬁc quintiles of increasing height (Q1–Q5) using multivariable Cox regression
models adjusted for demographics, comorbid conditions, lifestyle and disability indicators, socioeco-
nomic status, and body weight. For men, compared with the referent quintile (Q1 ,167 cm), successive
height quintiles had signiﬁcantly increased hazard ratios (HRs [95% conﬁdence interval]) for mortality: 1.04
(1.02–1.06), 1.08 (1.06–1.10), 1.12 (1.11–1.14), and 1.18 (1.16–1.20) for Q2–Q5, respectively. For women
(referentQ1,155 cm), HRs formortality were 1.00 (0.99–1.02), 1.05 (1.03–1.06), 1.05 (1.03–1.07), and 1.08
(1.06–1.10) for Q2–Q5, respectively. However, stratiﬁcation by race showed the pattern of association
differed signiﬁcantly by race (P,0.001 for interaction). For blackmen, unlike other race groups, height only
associated with mortality in Q5, with an HR of 1.06 (1.02–1.09). For black women, HRs for mortality were
0.94 (0.91–0.97), 0.98 (0.95–1.02), 0.96 (0.93–0.99), and 0.99 (0.96–1.02) for Q2–Q5, respectively. These
results indicate tallness is associated with higher mortality risks for adults starting dialysis, but this asso-
ciation did not extend to black patients.
J Am Soc Nephrol 27: 580–593, 2016. doi: 10.1681/ASN.2014080821
Adulthood height is an anthropometric measure-
ment that is determined by one’s genetic makeup
in addition to the interplay of several childhood
and adolescence environmental factors including
intercurrent illness, nutrition, and socioeconomic
circumstances.1–5 Therefore, it is not surprising
that the attained adult height is considered an im-
portant marker of early life health. Prospective
population-based epidemiology studies, in gen-
eral, have found an inverse association between
adult height and the risk of death from all causes,6–9
supporting the hypothesis that early life and child-
hood factors affect survival in adulthood. Al-
though the evidence linking tallness to an increased
life expectancy is generally robust, these ﬁndings
have not been consistently demonstrated in all
studies.9–11 Furthermore, cause-speciﬁc analyses
have found that increasing height is associated
with lower mortality from coronary disease but
higher mortality from speciﬁc cancers.10–15 These
divergent associations of height with mortality
would suggest that the relationships between
height and death are quite complex and may in-
ﬂuence survival through potentially different
mechanisms.10
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Height measurements are routinely captured in patients
who develop ESRD and require dialysis therapies.16 Surpris-
ingly, however, few published studies have explored the nature
of the relationship of adult height with mortality among pa-
tients undergoing dialysis.17 Most published studies to date
have evaluated the association of several anthropometric
measures of health including weight, body mass index and
waist circumference with major outcomes in order to examine
their clinical importance.18–22 However, to the best of our
knowledge none of these have explored the individual contri-
bution of height to mortality in a sufﬁciently robust manner.
Deﬁning the nature of height-mortality relationship in ESRD
would help us better understand the biologic importance of
height as an index of childhood health and as a prognostic
indicator of patient survival. For example, it is unclear if
the survival beneﬁt of tallness over shortness observed in the
general population is maintained following the initiation of
dialysis. Second, it remains to be determined whether associ-
ations of height withmortality can be accounted for by burden
of illness present at the start of dialysis or variation in care
patterns and treatment strategies prior to or after the initiation
of dialysis.23–27 Third, given the importance of race in survival
analysis in ESRD, it is tempting to speculate that any height-
mortality differences might vary across existing racial sub-
groups.
To improveour understanding of anthropometricmeasures
and their relationships with survival, we explored associations
of adulthood height with mortality in a large contemporary
cohort of patients from the US Renal Data System (USRDS)
who began dialysis from 1995 to 2008. We hypothesized that
tallness was associated with better survival as observed in the
general population and that any apparent height-mortality
relationships were independent of pre-existing baseline health
status, socioeconomic circumstances, and predialysis care
patterns.
RESULTS
Baseline Characteristics of Study Cohort
The study cohort included 1,171,842 individuals who com-
menced dialysis therapy between 1995 and 2008 (Figure 1).
The mean age of subjects was 62.9 years, 54% were male, and
the majority was white. The average height (6SD) for men
and women was 173.9 (9.6) cm and 160.6 (8.6) cm, respec-
tively. Black men were the tallest at 175.2 (9.8) cm followed by
white 173.8 (9.3) cm andAmerican Indian/Alaska native 173.8
(8.7) cm, while Asian men were the shortest at 166.4 (9.0) cm.
Similarly, black women were signiﬁcantly taller than white
women and American Indian/Alaska native (162.3 [8.6] cm
versus 160.0 [8.4] cm and 160 [7.9] cm, respectively) while
Asian women were signiﬁcantly shorter at 155 (8.5) cm. The
average age decreased with increasing height quintiles for both
men and women and the age-adjusted characteristics of adult
men and women by height quintile are presented in Tables 1
and 2. Taller men and women were more likely to be black,
non-Hispanic, have higher mean body weight, serum creati-
nine, and serum albumin than shorter individuals. Peripheral
vascular disease, chronic lung disease, and malignancy were
more common in tall men and women. Predialysis care in-
cluding visits from a nephrologist or dietitian was more com-
mon in tall men and women as was full or part employment.
Age-Adjusted Mortality Rates Across Height Quintiles
by Race and Sex
Patients were followed up for an average of 1.63 years. A total of
473,638 (40.42%) patients died, 65,799 (5.62%) were trans-
planted, and5654 (0.48%)were lost to follow-up.Amongmen,
mortality rates increased signiﬁcantly with rising quintile of
height although there was signiﬁcant heterogeneity across race
groups (Figure 2A). Among white, and to a lesser extent Asian
and American Indians/Alaska natives, increases in death rates
were observed with rising height quintile. However for black
race, rates decreased signiﬁcantly from the ﬁrst to the ﬁfth
quintile. For women, the pattern of association was similar
but not as striking (Figure 2B).
Associations of Height with Mortality by Sex and Race
The age-adjusted and multivariable-adjusted hazard ratios
(HRs) fordeathwith increasingquintile of height are shown for
men in Table 3. With adjustment for age, the HRs increased
signiﬁcantly and were highest for the highest quintile (HR,
Figure 1. Selection process of the study population frommerging
of the USRDS standard analysis ﬁles.
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1.06; 95% conﬁdence interval [95%CI], 1.05–1.07) compared
with the referent (Q1 ,167 cm; HR=1.00). With additional
adjustment for baseline characteristics, the HR was virtually
unchanged. When weight was included as a covariate in the
model, themagnitude of risk associated with increasing height
quintile was greatly magniﬁed especially for those in the high-
est quintile group (HR, 1.18; 95% CI, 1.16–1.20).
The relationship between height and mortality varied
signiﬁcantly across race groups (P value for interaction
,0.001) and the HR for each race subgroup is described in
Table 3. The corresponding smoothed
spline hazard functions are illustrated in
Figures 3A–D. The height-mortality rela-
tionships were positive and strongest for
white men, American Indians/Alaska na-
tives and Asian men as illustrated. In each
of these analyses, the extended model with
adjustment for the weight covariate resul-
ted in signiﬁcantly higher HR for death.
For black men, however, the pattern was
signiﬁcantly different. Both in the unad-
justed and themultivariate adjustedmodel,
increasing height was associated with sig-
niﬁcantly lower mortality (HR, 0.91; 95%
CI, 0.88–0.94 for the highest quintile ver-
sus the referent). When weight was added
to the model, the HR only changed mar-
ginally and became positive only for the
highest quintile group.
The age-adjusted and multivariable-
adjusted HRs for death with increasing
quintile of height are shown for women in
Table 4 and Figures 3A–D. In general these
associations paralleled those observed in
men, although the associations were much
weaker and not all were statistically signiﬁ-
cant. Again evidence of signiﬁcant heteroge-
neity was present across race groups with
white women showing a positive association,
while black women showed an inverse
association.
The robustness of our observations was
conﬁrmed in several sensitivity analyses.
First, we stratiﬁed the cohort by dialysis
modality and examined associations of
height with mortality separately for hemo-
dialysis (HD) and peritoneal dialysis (PD).
In these series of analysis, increasing height
was associated with elevated mortality for
both dialysis subgroups, although the pat-
tern was accentuated in HD (Supplemental
Table 1). Within HD, we speciﬁcally exam-
ined whether the association of height with
mortality was inﬂuenced by the number of
treatment hours of dialysis prescribed per
week. In contrast, we found that taller patients weremore likely
to receive longer treatment times but the pattern of higher
mortality with increasing height persisted irrespective of
whether patients were prescribed exactly 9 hours or exactly
12 hours treatment per week (Supplemental Table 2). The du-
ration of the treatment did inﬂuence the height-mortality
association and was more marked among patients who had
received shorter treatments (P,0.01 for interaction). Second,
neither vascular access type nor the duration of predialysis
nephrology care modiﬁed the association of height with
Figure 2. Age-adjusted mortality rates for (A) men and (B) women by race group across
height quintiles in the United States ESRD population. P,0.001 for all group com-
parisons.
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mortality. Third, we imputed missing data for explanatory var-
iables used in the adjusted models for the 636,594 men and
535,248women. This analysis yielded results that were virtually
identical to the original (Supplemental Table 3). Fourth, we
evaluated the impact of dialysis vintage on the height-mortality
relationship by recalculating the HR among survivors at 1, 2,
and 3 years after dialysis initiation. Again, in these series of
analyses, the pattern of mortality with increasing height was
virtually unchanged (Supplemental Table 4) and persisted after
5-year follow-up (Supplemental Tables 5 and 6). Finally, in a
series of further analyses, where we excluded kidney transplan-
tation as a censoring variable, the general pattern of elevated
mortality with increasing tallness persisted.
DISCUSSION
The ﬁndings from this large representative study of United
States dialysis patients demonstrate that increasing adult
height is directly and independently associated with mortality.
This association of tallness with elevated mortality was pre-
sent for both men and women who began dialysis treatment
although the relationshipwas generally weaker inwomen. Our
analyses uncovered an important effectmodiﬁcation of race on
the height-mortality risk association. Increasing height was
directly associated with higher mortality risks for whites,
Asians and American Indians/Alaska natives with the excep-
tionof blackmenandblackwomen,where heightwas inversely
Table 3. Unadjusted and multivariable adjusted HRs for death among men by height quintile stratiﬁed by race
Quintile group
Continuous Q1 Q2 Q3 Q4 Q5
(per 5 cm increase) <167 cm 167–172 cm 173–177 cm 178–181 cm ‡182 cm
HR (95% CI)a Referent quintile HR (95% CI)a HR (95% CI)a HR (95% CI)a HR (95% CI)a
Overall
Age adjusted 1.00 (1.00–1.01) 1.00 1.00 (0.99–1.02) 1.02 (1.01–1.04) 1.03 (1.02–1.04) 1.06 (1.05–1.07)
Multivariate adjustedb 1.00 (1.00–1.01) 1.00 1.01 (0.99–1.02) 1.02 (1.00–1.03) 1.03 (1.01–1.04) 1.04 (1.03–1.06)
Plus weightc 1.02 (1.02–1.03) 1.00 1.04 (1.02–1.06) 1.08 (1.06–1.10) 1.12 (1.10–1.14) 1.18 (1.16–1.20)
Plus dietitian visitd 1.02 (1.02–1.03) 1.00 1.03 (1.01–1.06) 1.07 (1.05–1.10) 1.11 (1.08–1.14) 1.16 (1.13–1.20)
Plus nephrology visitd 1.02 (1.02–1.03) 1.00 1.04 (1.01–1.07) 1.08 (1.05–1.11) 1.12 (1.09–1.15) 1.17 (1.14–1.20)
White
Age adjusted 1.01 (1.01–1.01) 1.00 1.00 (0.99–1.02) 1.02 (1.01–1.04) 1.04 (1.03–1.06) 1.08 (1.07–1.10)
Multivariate adjustedb 1.01 (1.01–1.01) 1.00 1.01 (0.99–1.02) 1.03 (1.01–1.04) 1.05 (1.03–1.06) 1.07 (1.05–1.09)
Plus weightc 1.03 (1.02–1.03) 1.00 1.03 (1.02–1.05) 1.08 (1.06–1.10) 1.13 (1.11–1.15) 1.19 (1.17–1.22)
Plus dietitian visitd 1.03 (1.02–1.04) 1.00 1.03 (1.00–1.06) 1.07 (1.04–1.11) 1.12 (1.09–1.16) 1.20 (1.16–1.24)
Plus nephrology visitd 1.03 (1.02–1.04) 1.00 1.03 (1.00–1.07) 1.08 (1.05–1.11) 1.13 (1.10–1.17) 1.21 (1.17–1.25)
Black
Age adjusted 0.97 (0.97–0.98) 1.00 0.94 (0.91–0.96) 0.90 (0.87–0.92) 0.85 (0.82–0.87) 0.87 (0.85–0.89)
Multivariate adjustedb 0.98 (0.98–0.99) 1.00 0.97 (0.94–1.00) 0.93 (0.90–0.96) 0.89 (0.86–0.92) 0.91 (0.88–0.94)
Plus weightc 1.00 (1.00–1.01) 1.00 0.99 (0.96–1.03) 0.99 (0.96–1.02) 0.99 (0.96–1.02) 1.06 (1.02–1.09)
Plus dietitian visitd 1.00 (0.99–1.01) 1.00 0.99 (0.93–1.05) 0.99 (0.93–1.05) 0.98 (0.92–1.04) 1.02 (0.96–1.08)
Plus nephrology visitd 1.00 (0.99–1.01) 1.00 0.99 (0.93–1.05) 0.99 (0.94–1.05) 0.98 (0.93–1.05) 1.02 (0.96–1.08)
Asian
Age adjusted 0.98 (0.97–0.99) 1.00 0.92 (0.87–0.98) 1.02 (0.94–1.09) 1.03 (0.93–1.15) 1.10 (0.95–1.26)
Multivariate adjustedb 0.98 (0.97–1.00) 1.00 0.94 (0.88–1.01) 1.02 (0.93–1.11) 1.01 (0.90–1.15) 1.01 (0.85–1.19)
Plus weightc 1.00 (0.99–1.02) 1.00 1.00 (0.93–1.07) 1.12 (1.03–1.23) 1.17 (1.03–1.33) 1.22 (1.03–1.45)
Plus dietitian visitd 0.99 (0.96–1.02) 1.00 1.00 (0.89–1.13) 1.12 (0.97–1.30) 1.22 (0.99–1.50) 1.07 (0.79–1.43)
Plus nephrology visitd 0.99 (0.96–1.01) 1.00 1.00 (0.88–1.12) 1.12 (0.96–1.30) 1.21 (0.98–1.49) 1.06 (0.79–1.42)
American Indian/Alaska native
Age adjusted 1.01 (0.99–1.04) 1.00 1.07 (0.92–1.24) 1.00 (0.87–1.15) 1.08 (0.93–1.25) 1.12 (0.96–1.31)
Multivariate adjustedb 1.02 (0.99–1.05) 1.00 1.18 (1.00–1.39) 1.10 (0.93–1.29) 1.12 (0.95–1.33) 1.17 (0.98–1.39)
Plus weightc 1.04 (1.01–1.08) 1.00 1.20 (1.02–1.42) 1.15 (0.97–1.35) 1.21 (1.01–1.44) 1.28 (1.07–1.54)
Plus dietitian visitd 0.98 (0.93–1.03) 1.00 1.03 (0.77–1.37) 0.92 (0.69–1.22) 1.01 (0.75–1.37) 0.84 (0.60–1.17)
Plus nephrology visitd 0.98 (0.93–1.03) 1.00 1.06 (0.80–1.41) 0.92 (0.70–1.23) 1.03 (0.76–1.39) 0.85 (0.61–1.18)
CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration.
aHRs and 95% CIs.
bMultivariable model adjusted for: age, cause of end-stage kidney disease, co-morbid conditions at time of dialysis initiation (coronary artery disease, peripheral
vascular disease, heart failure, stroke, hypertension, diabetes, chronic lung disease, and malignancy), lifestyle factors (current smoker status, drug and alcohol
addiction), functional status indicators (inability to ambulate, inability to transfer independently), socioeconomic factors (employment status, insurance status at
time of dialysis), baseline eGFR (from the CKD-EPI equation), albumin, and use of erythropoietin prior to dialysis initiation, incident year of cohort.
cBody weight measured prior to ﬁrst dialysis treatment was included in extended model to account for differences in body size.
dVisit with a nephrologist or dietitian was substituted for pre-dialysis erythropoietin in extended models to account for differences in care patterns prior to dialysis
initiation.
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related to mortality. The observations from this study con-
trast with ﬁndings from the general population and show for
the ﬁrst time that tallness does not contribute to greater life
expectancy for the majority of patients who reach ESRD.
The present study sheds new light on the patterns of as-
sociationof heightwithmortality amongmen andwomenwho
developESRD.Although studies in the general populationhave
suggested that the beneﬁt associatedwith tallness is uniformly
positive,6–9 this study has found the contrary. Taller patients
did not achieve greater lifespans than shorter patients. We
had speculated that this new ﬁnding may well reﬂect the fact
that taller persons with advanced kidney disease had ac-
cumulated a greater burden of illness during the predialysis
period prior to dialysis initiation. Indeed, comparisons of
quintile groups at baseline found higher prevalence of several
chronic diseases including chronic lung disease, peripheral
vascular disease, and malignancy in taller compared with
shorter individuals. Yet whenwe accounted for these baseline
differences in the multivariable models, the pattern of as-
sociation of height with elevated mortality was virtually
unchanged.
To assess fully the independence of this new association
of height with elevated mortality, we carefully considered
several situationswhere patient-level or treatment-level factors
may have confounded the relationship. When we stratiﬁed
by dialysis modality, we found that the relationship of height
withmortality for patients undergoingHDwas similar to those
of the original analysis. The pattern was identical even when
accounting for vascular access type. Furthermore, when we
evaluated the relationship of height with mortality according
Figure 3. Association of height with hazard ratio of death by race group for men and for women. Height mortality relationships for (A)
whites, (B) blacks, (C) Asians, and (D) American Indians/Alaska natives. Height was modeled by a restricted cubic spline with four knots
placed at the 20th, 40th, 60th and 80th percentiles of height for men and women, respectively. Models are adjusted for age, cause of
ESRD, comorbid conditions at time of dialysis (coronary artery disease, peripheral vascular disease, heart failure, stroke, hypertension,
diabetes, chronic lung disease, andmalignancy), lifestyle factors (smoking status, drug and alcohol addiction), functional status indicators
(inability to ambulate, inability to transfer independently), socioeconomic factors (employment status, insurance status at time of dialysis),
baseline eGFR (from the CKD-EPI equation), albumin, use of erythropoietin prior to dialysis initiation, and incident year of cohort. HRs
with 95% CI in dotted lines. CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration.
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to the duration of dialysis prescribed per week, we found that
taller individuals experienced signiﬁcantly higher mortality
risks irrespective of whether they received 9 hours or 12 hours
of treatment, although the risks were accentuated for those
who were prescribed shorter treatment times. For patients
treatedwith PD, the patterns of associationwithmortalitywere
similar to HD but far more striking in men than in women.
These ﬁndings would suggest that the relationship of height
with mortality is independent of the treatment strategy in-
cluding the number of hours prescribed per week.
Prior studies have demonstrated that differences in the
delivery of care prior to the onset of dialysis may inﬂuence
patient survival following dialysis initiation.26,27 We carefully
examined whether the association of height with mortality
might have been inﬂuenced by differential access to nephrol-
ogy care or the duration of care prior to dialysis initiation. Our
analysis revealed that greater proportions of taller patients re-
ceived care from a nephrologist or dietitian in the period pre-
ceding dialysis initiation. As before, when we adjusted for
these differences in predialysis care patterns, the results were
visibly unchanged. We also considered the possibility that
missing data on important explanatory covariates might
have altered our results; however, our multiple imputation
strategy for missingness gave rise to similar ﬁndings. Fi-
nally, we demonstrated that the pattern of mortality risk was
consistent among survivor cohorts at 1 year, 2 years, and up to
Table 4. Unadjusted and multivariable adjusted HRs for death among women by height quintile stratiﬁed by race
Quintile group
Continuous Q1 Q2 Q3 Q4 Q5
(per 5 cm increase) <155 cm 155–159 cm 160–162 cm 163–167 cm ‡168 cm
HR (95% CI) Referent quintile HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Overall
Age adjusted 1.00 (1.00–1.01) 1.00 0.99 (0.98–1.01) 1.02 (1.00–1.03) 1.02 (1.01–1.03) 1.03 (1.01–1.04)
Multivariate adjustedb 1.00 (1.00–1.00) 1.00 0.98 (0.97–1.00) 1.01 (0.99–1.03) 1.00 (0.99–1.02) 1.00 (0.99–1.02)
Plus weightc 1.01 (1.01–1.02) 1.00 1.00 (0.99–1.02) 1.05 (1.03–1.06) 1.05 (1.03–1.07) 1.08 (1.06–1.10)
Plus dietitian visitd 1.02 (1.01,1.02) 1.00 1.02 (0.99–1.05) 1.06 (1.02–1.09) 1.07 (1.04–1.11) 1.09 (1.06–1.13)
Plus nephrology visitd 1.02 (1.01,1.02) 1.00 1.02 (0.99–1.05) 1.06 (1.02–1.09) 1.07 (1.04–1.11) 1.09 (1.06–1.13)
White
Age adjusted 1.01 (1.01–1.02) 1.00 1.00 (0.99–1.02) 1.03 (1.01–1.05) 1.05 (1.04–1.07) 1.08 (1.06–1.10)
Multivariate adjustedb 1.01 (1.01–1.02) 1.00 1.00 (0.98–1.02) 1.03 (1.01–1.05) 1.04 (1.02–1.06) 1.06 (1.04–1.08)
Plus weightc 1.02 (1.02–1.03) 1.00 1.02 (1.00–1.04) 1.06 (1.04–1.08) 1.08 (1.06–1.10) 1.12 (1.10–1.15)
Plus dietitian visitd 1.03 (1.02,1.03) 1.00 1.02 (0.99–1.06) 1.07 (1.03–1.12) 1.11 (1.07–1.15) 1.14 (1.09–1.18)
Plus nephrology visitd 1.03 (1.02,1.03) 1.00 1.03 (0.99–1.06) 1.07 (1.03–1.12) 1.11 (1.07–1.15) 1.14 (1.09–1.18)
Black
Age adjusted 0.98 (0.98–0.98) 1.00 0.92 (0.89–0.95) 0.92 (0.90–0.95) 0.90 (0.88–0.92) 0.90 (0.87–0.92)
Multivariate adjustedb 0.98 (0.98–0.99) 1.00 0.92 (0.89–0.95) 0.95 (0.91–0.98) 0.91 (0.89–0.94) 0.91 (0.88–0.93)
Plus weightc 1.00 (0.99–1.00) 1.00 0.94 (0.91–0.97) 0.98 (0.95–1.02) 0.96 (0.93–0.99) 0.99 (0.96–1.02)
Plus dietitian visitd 1.00 (0.99–1.01) 1.00 0.94 (0.88–1.00) 0.98 (0.92–1.05) 0.97 (0.92–1.03) 0.99 (0.93–1.05)
Plus nephrology visitd 1.00 (0.99–1.01) 1.00 0.94 (0.89–1.00) 0.98 (0.92–1.05) 0.97 (0.91–1.03) 0.98 (0.93–1.04)
Asian
Age adjusted 1.00 (0.98–1.01) 1.00 0.96 (0.90–1.02) 0.99 (0.9–1.08) 1.06 (0.97–1.16) 1.09 (0.97–1.22)
Multivariate adjustedb 0.99 (0.97–1.01) 1.00 0.94 (0.88–1.02) 0.97 (0.87–1.08) 1.01 (0.91–1.12) 1.04 (0.91–1.20)
Plus weightc 1.00 (0.98–1.02) 1.00 0.97 (0.90–1.04) 1.01 (0.90–1.12) 1.07 (0.96–1.19) 1.14 (0.99–1.31)
Plus dietitian visitd 1.02 (0.93–1.05) 1.00 1.02 (0.89–1.17) 0.97 (0.80–1.18) 1.09 (0.90–1.32) 1.27 (0.99–1.63)
Plus nephrology visitd 1.02 (0.98–1.06) 1.00 1.02 (0.89–1.17) 0.97 (0.80–1.17) 1.09 (0.90–1.32) 1.27 (0.98–1.63)
American Indian/Alaska native
Age adjusted 1.02 (0.99–1.04) 1.00 0.93 (0.82–1.05) 0.91 (0.78–1.05) 0.99 (0.87–1.13) 1.08 (0.94–1.25)
Multivariate adjustedb 1.00 (0.97–1.03) 1.00 0.93 (0.81–1.08) 0.90 (0.76–1.07) 0.95 (0.82–1.11) 1.00 (0.85–1.17)
Plus weightd 1.02 (0.98–1.05) 1.00 0.96 (0.83–1.11) 0.93 (0.78–1.1) 1.00 (0.86–1.16) 1.08 (0.91–1.28)
Plus dietitian visitd 1.05 (0.99–1.12) 1.00 1.01 (0.76–1.34) 0.86 (0.62–1.2) 1.00 (0.74–1.36) 1.27 (0.92–1.76)
Plus nephrology visitd 1.05 (0.98–1.12) 1.00 1.01 (0.76–1.34) 0.88 (0.63–1.2) 1.00 (0.74–1.35) 1.26 (0.92–1.74)
CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration.
aHRs and 95% CIs.
bMultivariable model adjusted for: age, cause of end stage kidney disease, comorbid conditions recorded at time of dialysis initiation (coronary artery disease,
peripheral vascular disease, heart failure, stroke, hypertension, diabetes, chronic lung disease, and malignancy), lifestyle factors (current smoker, drug and alcohol
addiction), functional status indicators (inability to ambulate, inability to transfer independently), socioeconomic factors (employment status, insurance status at
time of dialysis), baseline eGFR (from the CKD-EPI equation), albumin, and use of erythropoietin prior to dialysis initiation, incident year of cohort.
cBody weight measured prior to ﬁrst dialysis treatment was included in extended model to account for differences in body size.
dVisit with a nephrologist or dietitian was substituted for pre-dialysis erythropoietin use in extended models to account for differences in care patterns prior to
dialysis initiation.
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3 years after dialysis initiation. These observations would
suggest that the prognostic importance of height on mortality
is independent of baseline health at dialysis initiation and
associated care delivery practices provided prior to dialysis
initiation.
An interesting but perplexing ﬁnding was the divergent risk
associations of race on the height-mortality association. The
strong interaction between race and height with mortality was
present for men and women, and in each case tallness among
blacks was inversely associated with all-cause mortality. The
reasons for these differences between blacks and whites are
unknown. As ﬁnal adult height is largely determined by both
genetic and environmental factors,1 we surmised that differ-
ences in the distribution of these factors between black and
non-blacks may account for these differences. We found that
black men and women, compared with their white counter-
parts, were younger in age and had a lower prevalence of di-
abetes, coronary disease, and heart failure, factors that may
have given them a favorable survival advantage. Taller indi-
viduals had better socioeconomic circumstances with higher
proportions in employment, in receipt of health insurance and
predialysis care. Although white and black patients should
beneﬁt equally from these socioeconomic supports, it is pos-
sible that black patients beneﬁted proportionally more from
these factors at dialysis initiation. Given that height is a poly-
genic trait with up to 90% heritability, it is equally plausible
that genes associated with height may exhibit different effects
in blacks compared with whites.28 In support of this hypoth-
esis, studies comparing blacks with whites have found signif-
icantly greater bone mineral density, bone mineral content,
skeletal weight, and body protein content in blacks than in
whites, adjusting for weight, height and age.29
A striking feature of the current study is the loss of survival
beneﬁt for tall white patients, ﬁndings that contrast with the
generalUnited States population. Prospective cohort studies of
white men and women have convincingly shown that taller
individuals experience lower death risks from all causes.6–9
Paradoxically, tallness among white patients undergoing dial-
ysis appears to be an adverse risk marker, compared with the
general white population. These seemingly discordant ﬁnd-
ings may well represent a reverse epidemiologic ﬁnding that
is commonly observed with certain cardiovascular risk factors
in ESRD.30–32 In this scenario, factors which are usually asso-
ciated with positive effects on survival exhibit deleterious ef-
fects in speciﬁc populations with chronic conditions. It is also
possible that the adverse impact of height on mortality among
whites may be partly related to higher cancer mortality
rates.13,15 The Emerging Risk Factors Collaboration study
found a 4% increase in cancer mortality risk for men and a
5% increase for women with each 6.5 cm increase in height.15
This study is notwithout limitations.Heightmeasurements
were self-reported and the exact timing of measurements for
patients was not available although physicians were instructed
to record the most recent height measurement prior to ﬁrst
dialysis. While an extensive list of comorbid conditions is
captured from the Medical Evidence Form, the severity of
disease was not available. We also accept that this study, while
representative of the United States dialysis populationmay not
represent patients from countries outside the United States.
Although our analyses captured data on the durationof dialysis
treatments in HD, we lacked information on dialysis dose, an
important determinant of survival from prior studies.33,34 It is
also possible that residual bias may inﬂuence our results due to
unmeasured or imprecisely measured confounders. The lim-
itations of this study were counterbalanced by several
strengths. The large sample size of over 1 million patients
provided a powerful mechanism to examine for effect modi-
ﬁcation and test hypotheses in several subgroups. Mandatory
participation in the United States registry ensures that our
results are generalizable to the entire United States dialysis
population. TheUSRDS captured data onmultiple confounders
including comorbid disease, laboratory variables, socioeco-
nomic factors, and care delivery patterns allowing us to exam-
ine in great detail the independence of the height-mortality
relationship. The availability of data on body weight prior to
dialysis initiation provided us with an additional opportunity
to account for the inﬂuence of weight in the height-mortality
relationship.
In this population based study of over 1 million new dialy-
sis patients, we observed a strong independent association of
height with elevated mortality. This ﬁnding was present for
men and for women andmost race groups except blacks where
the association was inversely related with mortality. This re-
lationship was not explained by prevailing burden of medical
illness, differences in socioeconomic factors or care practices
prior to or after dialysis initiation. Contrary to ﬁndings in the
general population, there was no overall survival beneﬁt of
tallness over shortness in the majority of patients who reach
ESRD.
CONCISE METHODS
The study population represented a historical prospective cohort of
1,171,842 United States patients, who began dialysis between May 1,
1995 and December 31, 2008, and had follow-up until December 31,
2010. Data sufﬁcient for these analyses were obtained from merged
standard analysis ﬁles (SAFs) of the USRDS.13 The Medical Evidence
SAF is derived from the Center for Medicare and Medicaid Services
(CMS)Medical Evidence Form, a government document that is com-
pleted for all new patients initiated on dialysis.35 The CMS form
captures data on demographic characteristics, anthropometric mea-
sures, comorbid conditions, measures of functional status, laboratory
indices, and date and type of dialysis treatment provided for all in-
cident patients. The form is completed by medical personnel who
care for patients in each dialysis facility through data abstraction from
patients’ medical records. The following variables were included for
our analyses: height (cm), age, gender, race (classiﬁed as white, black,
Asian and American Indian/Alaska native, cause of ESRD, comorbid
conditions including: diabetes, hypertension, coronary artery
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disease, peripheral arterial disease, stroke, diabetes, congestive heart
failure, chronic lung disease,malignancy, alcohol use, drug dependence,
smoking, inability to ambulate and transfer independently, current
employment status, insurance status, and measures of predialysis
care. Laboratory data included hematocrit, serum albumin and
creatinine measured at or prior to dialysis initiation. Residual renal
function at dialysis initiation was estimated from estimated GFR
using the Chronic Kidney Disease Epidemiology Collaboration.36
The study had approval from the Ethics Committee at University
Hospital Limerick in accordance with the Declaration of Helsinki.
Cohort Assembly
The medical evidence (n=1,753,496 patients) and mortality ﬁles
(n=2,377,166 patients) were merged to create the ﬁnal analytic data-
set (Figure 1). After merging and removal of duplicate patients, we
then excluded patients with missing or unknown race, date of ﬁrst
treatment before May 1995, unknown sex, cause of ESRD unknown,
age,18 or.100 and medical evidence forms completed before May
1, 1995. This left us with 1,445,980 patients. Next, we excluded pa-
tients with missing height or weight (n=51,538) and ﬁnally patients
where the date of ﬁrst treatment was post December 2008
(n=222,600). There were 1,171,842 patients in the ﬁnal study cohort.
Height Measurements for Men and Women
Height was recorded at the beginning of dialysis treatment for all
patients and categorized in sex-speciﬁc quintiles (Q). For men the
height quintiles were: Q1,167 cm, Q2 167–172 cm, Q3 173–177 cm,
Q4 178–181 cm, and Q5 $182 cm. For women, the corresponding
quintiles were: Q1 ,155 cm, Q2 155–159 cm, Q3 160–162 cm, Q4
163–167 cm, and Q5 $168 cm. These ten categories allowed a de-
tailed examination of the association between height and mortality
across a wide range of height values without prior assumptions re-
garding the shape of any dose–response curve.
Mortality Assessment
Mortality data were derived from two sources, the CMS death no-
tiﬁcation form and the Social Security Administration’s death mas-
ter ﬁle.13 Together these provide the date and cause of death for all
patients who received renal replacement therapy in the United States.
Death from all causes was the primary end point for all analyses.
Statistical Analysis
Age-adjustedbaseline characteristics according to eachheight quintile
were obtained for men and for women using direct standardization.
The reference population was the entire cohort of 1,171,842 patients
who began dialysis treatment betweenMay 1995 and December 2008.
Multiple linear regression and logistic regressionmodels were used to
test for linear trends in height, adjusting for age.
Two-year mortality rates were calculated for each race and sex group
as thenumberof death events dividedby person-timeof follow-up.Mortal-
ity rates were age adjusted using direct standardization. Cox regression
models were used to describe the relationship between height quintile
andmortality adjusting for age, race, cause of ESRD, comorbid conditions,
laboratory variables, lifestyle indicators, and socioeconomic measures. In
addition, we adjusted for the weight of patients recorded prior to ﬁrst
dialysis to account for its prognostic impact on mortality. Multivariate
adjusted HRs for each height quintile (using the ﬁrst quintile as
referent) and associated 95% CIs were determined. By adding an
interaction term between height quintile and race, we found that the
effect of height on mortality varied signiﬁcantly by race group
(P,0.001) among men and among women. For this reason, the ﬁnal
analyses were stratiﬁed by race. The functional relationship between
height and death was further examined in a series of restricted cubic
spline functions with four knots placed at the 20th, 40th, 60th, and
80th percentiles of height for men and women, respectively. The
proportional hazards assumption was checked by including a sur-
vival time ☓ height quintile interaction in the full model. The
primary analyses were conducted using non-missing data on all
covariates using SAS v9.3 software (SAS Institute, Inc., Cary, NC).
Sensitivity Analysis
We conducted a series of carefully constructed additional analyses
to evaluate the robustness of our results. First, we examinedwhether the
association of height with mortality differed by dialysis modality (HD
and PD), and by the number of hours of dialysis prescribed per week, as
taller patients may preferentially have been directed toward a particular
modality and prescribed longer treatments. Second,we further explored
whetherourﬁndings differedby the presence anddurationofpredialysis
nephrologycareandbyvascularaccess typeatdialysis initiation.Third, to
account for possible bias due to different missing data patterns across
height quintiles, we imputedmissing covariate data for the 636,594men
and 535,248women inTables 1 and 2 and repeated the original analyses.
Missing covariate information was imputed by ﬁrst estimating a joint
multivariate normal distribution for all covariates and then simulating
missing covariates from the appropriate conditional distributions. Iden-
tical multivariate models were ﬁtted to three independently imputed
datasets. In each case, the log HRs and associated standard errors were
combined using the SAS procedure MIanalyze to produce a single log
HR and standard error for each model. Fourth, we assessed whether
the relationships observed differed by different dialysis vintage by
repeating the analyses at intervals of 1, 2, 3, and 4 years. We also
extended follow-up to 5 years to assess the association of height on
long-term mortality. Fifth, we removed kidney transplantation as a
censoring variable as we surmised that patient height may be corre-
lated with the risk of transplantation thereby creating a potential
survival bias. Finally, we assessed the external validity of our results
to that of the general United States dialysis population by comparing
individuals who were excluded at baseline with those who were in-
cluded in the ﬁnal analysis.
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